|
Name |
Preaustinoid A2
|
| Molecular Formula | C26H34O7 | |
| IUPAC Name* |
methyl (1R,2S,5S,11S,12S,14R,16S)-16-hydroxy-2,6,6,11,14,16-hexamethyl-18-methylidene-8,15,17-trioxo-7-oxatetracyclo[12.3.1.02,12.05,11]octadec-9-ene-1-carboxylate
|
|
| SMILES |
C[C@]12CC[C@H]3[C@]([C@@H]1C[C@@]4(C(=C)[C@]2(C(=O)[C@@](C4=O)(C)O)C(=O)OC)C)(C=CC(=O)OC3(C)C)C
|
|
| InChI |
InChI=1S/C26H34O7/c1-14-23(5)13-16-22(4)11-10-17(27)33-21(2,3)15(22)9-12-24(16,6)26(14,20(30)32-8)19(29)25(7,31)18(23)28/h10-11,15-16,31H,1,9,12-13H2,2-8H3/t15-,16+,22-,23-,24+,25+,26+/m1/s1
|
|
| InChIKey |
SGTJQTPUMKGFFZ-RFMSQVAGSA-N
|
|
| Synonyms |
Preaustinoid A2; CHEMBL4519119; CHEBI:156343; 8T0
|
|
| CAS | NA | |
| PubChem CID | 132274399 | |
| ChEMBL ID | CHEMBL4519119 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 458.5 | ALogp: | 3.4 |
| HBD: | 1 | HBA: | 7 |
| Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 107.0 | Aromatic Rings: | 4 |
| Heavy Atoms: | 33 | QED Weighted: | 0.362 |
| Caco-2 Permeability: | -5.363 | MDCK Permeability: | 0.00003330 |
| Pgp-inhibitor: | 0.875 | Pgp-substrate: | 0.129 |
| Human Intestinal Absorption (HIA): | 0.091 | 20% Bioavailability (F20%): | 0.96 |
| 30% Bioavailability (F30%): | 0.825 |
| Blood-Brain-Barrier Penetration (BBB): | 0.992 | Plasma Protein Binding (PPB): | 68.31% |
| Volume Distribution (VD): | 0.504 | Fu: | 33.15% |
| CYP1A2-inhibitor: | 0.003 | CYP1A2-substrate: | 0.978 |
| CYP2C19-inhibitor: | 0.103 | CYP2C19-substrate: | 0.773 |
| CYP2C9-inhibitor: | 0.039 | CYP2C9-substrate: | 0.024 |
| CYP2D6-inhibitor: | 0.003 | CYP2D6-substrate: | 0.009 |
| CYP3A4-inhibitor: | 0.936 | CYP3A4-substrate: | 0.951 |
| Clearance (CL): | 2.627 | Half-life (T1/2): | 0.249 |
| hERG Blockers: | 0.002 | Human Hepatotoxicity (H-HT): | 0.58 |
| Drug-inuced Liver Injury (DILI): | 0.763 | AMES Toxicity: | 0.115 |
| Rat Oral Acute Toxicity: | 0.077 | Maximum Recommended Daily Dose: | 0.636 |
| Skin Sensitization: | 0.187 | Carcinogencity: | 0.919 |
| Eye Corrosion: | 0.899 | Eye Irritation: | 0.342 |
| Respiratory Toxicity: | 0.982 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC005629 | ![]() |
0.411 | D0P0HT | ![]() |
0.254 | ||
| ENC005963 | ![]() |
0.406 | D0Q4SD | ![]() |
0.250 | ||
| ENC006004 | ![]() |
0.403 | D03ZZK | ![]() |
0.250 | ||
| ENC005188 | ![]() |
0.402 | D0H2MO | ![]() |
0.248 | ||
| ENC005318 | ![]() |
0.402 | D0IL7L | ![]() |
0.246 | ||
| ENC005250 | ![]() |
0.398 | D02JNM | ![]() |
0.244 | ||
| ENC002162 | ![]() |
0.392 | D0I5DS | ![]() |
0.242 | ||
| ENC005964 | ![]() |
0.389 | D0D2TN | ![]() |
0.242 | ||
| ENC005189 | ![]() |
0.388 | D04GJN | ![]() |
0.242 | ||
| ENC005317 | ![]() |
0.388 | D02QJH | ![]() |
0.237 | ||